Kornimate/medical-research-clean huggingface dataset:
extramedullary acute myeloid leukemia (eaml): retrospective single center cohort study, clinicopathological, molecular analysis and survival outcomes

Conditions: Acute Myeloid Leukemia

Summary: patients with extramedullary leukemia were identified over 10 years (january 2003 to september 2019). clinicopathological,genetic-molecular features were identified and survival outcomes were studied and analyzed.

we retrospectively collected patients demographics ,including clinicopathological and genetic-molecular parameters in patients with extramedullary leukemia between january 2003 till september 2019 from king hussein cancer center(khcc) electronic medical records. all potential prognostic factors were identified and compared with worldwide data published previously. treatment and survival outcomes were studies and analyzed. primary endpoint : overall survival (os). secondary endpoint : * progression free survival (pfs). * incidence of extramedullary leukemia.

Eligibility criteria:
inclusion criteria: * adult subjects aged ≥18 year and up to 75 years * male and females. * initially diagnosed and treated with extramedullary leukemia at khcc and followed till last encounter. * patients, who underwent an allogeneic stem cell transplant. * period january 2003-september 2019 exclusion criteria: * pediatric patients \<18 year of age * patients, who lost their follow up within study period.

Keywords: aml leukemia, myeloid sarcoma extramedullary disease
effect of modified fujita technique uvulopalatoplasty on oxidative dna damage levels in patients with obstructive sleep apnea syndrome (osas)

Conditions: Sleep Apnea, Obstructive

Summary: the purpose of this study is to determine the possible effects of uvulopalatopharngoplasty (uppp) -which is a a therapy used on patients with obstructive sleep apnea syndrome (osas- on oxidative damage.

obstructive sleep apnea syndrome (osas) is a sydrome which has characteristic upper way obstruction and a decrease in blood oxygen saturation as sleeping. uvulopalatopharngoplasty (uppp)is one of the surgical approaches applied to the patients with osas, since the oxidative damage markers have been found high in patients with osas. although antioxidant levels were higher in patients with osas than those in normal population, there is report about the effect of uppp on antioxidant status in patients with osas. we performed this study to confirm whether is there a we performed the present study to confirm whether there is a relationship between the osas and oxidative damage before and after uppp.

Eligibility criteria:
inclusion criteria: * patients who underwent uvulopalatopharngoplasty (uppp)for obstructive sleep apnea syndrome (osas) exclusion criteria: * anormal nasopharyngeal computed tomography, chronic diseases such as diabetes mellitus, hypertension etc.

Keywords: dna oxidation obstructive sleep apnea lipid peroxidation oxidative stresses
accurate recognition of exacerbation of chronic obstructive pulmonary disease (copd)

Conditions: Airway Obstruction

Summary: it has been observed that copd exacerbations are under-reported in china. one of the reasons for this is chinese subjects with copd cannot describe the symptoms of exacerbation mentioned in english. hence this study aims to create a tool called cert that will help chinese physicians and subjects with copd to recognize and report exacerbations. the study will be carried out in 4 stages: item identification, cognitive briefing, item reduction and creation of final certs. two certs will be prepared, one for subjects with copd and another for physicians. a total of approximately 200 subjects will be included in the study and each subject will contribute to only one step.


Eligibility criteria:
inclusion criteria: * male or female of age greater than or equal to 40 years. * spirometrically confirmed copd according to diagnostic criteria in global initiative for chronic obstructive lung disease (gold) 2016. * a treated exacerbation of copd within 3 months prior to the study visit. * willing and able to provide informed consent, and able to participate in focus groups or cognitive interviews. * literacy is not a requirement for any of the groups. exclusion criteria: * current diagnosis of asthma or clinically relevant bronchiectasis. note: subjects with asthma copd overlap syndrome (acos) are eligible. * subjects with a concurrent significant, uncontrolled, active medical condition or disease state of other organ diseases or systematic diseases; psychiatric condition; cognitive impairment or any other reasons that in the investigator's opinion, would place subjects at risk or interfere with study evaluation or affect participation in the study.

Keywords: china cognitive testing copd exacerbation cert
use of osteopathic manipulative treatment for non-musculoskeletal conditions

Conditions: Manipulation, Osteopathic

Summary: the goal of this observational study is to learn how clinicians use osteopathic manipulative treatment (omt) for their patients who have problems only related to their muscles, bones, and joints (ie, musculoskeletal problems) compared to patients whose problems involve other body systems (eg, infections, breathing, bowel function). the main questions it aims to answer are: * what percentage of patients receiving omt have a non-musculoskeletal problem? * is there a difference in the omt techniques when the patient's problems include a non-musculoskeletal problem compared to patients with only musculoskeletal problems? surveys will be completed by the clinicians about 20 unique adult (age 18 or older) patients who have received omt.


Eligibility criteria:
inclusion criteria: * adult patients receiving osteopathic manipulative treatment from a participating treatment provider exclusion criteria: -

Keywords: musculoskeletal diseases non-musculoskeletal diseases osteopathic manipulative treatment
feasibility of early gabapentin as an intervention for neurorecovery

Conditions: Spinal Cord Injuries

Summary: the objective of the proposed study is to conduct the first ever prospective, dose-exploration trial to test the feasibility of early administration of gabapentin as an intervention for neurorecovery. this research project falls under the intervention development stage of research as the primary goal is to assess the feasibility of conducting a well-designed intervention efficacy study in the future.

gabapentin is a medication commonly used in spinal cord injury (sci) to manage neuropathic pain. emerging preclinical and clinical evidence suggests that early initiation of low to medium doses of gabapentin and continued delivery for a range of 2 weeks to 4 months has a persistent, positive effect on motor and autonomic neurologic recovery. the objective of the proposed study is to conduct the first ever prospective, dose-exploration trial to test the early administration of gabapentin as an intervention for neurorecovery. a mock efficacy design will be employed. participants will be stratified based on asia impairment scale (ais) grade a-b or c-d and randomized to 1 of 3 arms. study medication will be initiated within 5 days post-injury and administered for 90 days. participants will be followed for an additional 90 days after stopping treatment.

Eligibility criteria:
inclusion criteria: 1. traumatic sci; 2. all levels of sci; 3. all severities of sci, ais a-d; 4. age 18 years and older. 5. agree to participate and start study drug within 120 hours' post-injury. 6. adequate cognition and communication to provide informed consent exclusion criteria: 1. presence of moderate/severe traumatic brain injury (tbi) as defined by glasgow coma score (gcs) \< 13 at 120 hours' post-injury. 2. documented use of gabapentinoids at the time of injury.

Keywords: gabapentin neurorecovery feasibility
detecting minimal residual diseases (mrd) and monitoring clonal evolution using ultrasensitive chromosomal aberrations detection (ucad) in multiple myeloma

Conditions: Multiple Myeloma

Summary: the presence of minimal residual disease (mrd) is an important prognostic factor for multiple myeloma, while copy number variation (cnv) is a widely accepted biomarker used for multiple myeloma (mm). detecting mrd and monitoring clonal evolution by monitoring cnv using low-pass whole genome sequencing is promising due to its high analytical sensitivity. to evaluate the correlation between mrd detected by flow cytometry and low-pass whole genome sequencing, nearly 200 samples were collected for this study. we applied ultrasensitive chromosomal aberrations detection to detect cnv for each patient. the follow-up samples were then collected and sequencing used the same method.


Eligibility criteria:
inclusion criteria: * subjects diagnosed with mm. * with available baseline and sequential next-generation flow-mrd data. exclusion criteria: * subjects without baseline and sequential next-generation flow-mrd data.

Keywords: minimal residual disease low-pass whole genome sequencing clonal evolution ultrasensitive chromosomal aberrations detection
uroxatral in men with benign prostate hypertrophy (bph) and erectile dysfunction (ed)

Conditions: BPH; Erectile Dysfunction

Summary: uroxatral (alfuzosin) may not only help bph symptoms but may also improve sexual function in males with bph and ed.

the study will consist of a 30 day screening/washout phase at the end of which qualified subjects will be assigned to alfuzosin 10 mg tablets once a day. subjects will be treated for 90 days. the total duration of the study will be 120 days.

Eligibility criteria:
inclusion criteria: * males 45-75 years of age * confirmed diagnosis of bph/lower urinary tract symptoms (luts) and ed * men with steady partner and who agree to attempt sex once a week. exclusion criteria: * prostate cancer * prostatitis * penile disease * cardiac co-morbidity * pre-existing co-morbid conditions * history of sensitivity to the drug or similar drugs * enrollment in another clinical trial * impaired hepatic function * impaired renal function * mental conditions rendering subject unable to understand the study * subjects not likely to comply with protocol
4-[18f]fluoroglutamine pet/ct in imaging patients with newly diagnosed lung cancer or indeterminate pulmonary nodules

Conditions: Lung Cancer; Solitary Pulmonary Nodule; Cigarette Smoking Behavior

Summary: this clinical trial studies positron emission tomography (pet) imaging utilizing 18f-(2s,4r)4-fluoroglutamine, a glutamic acid derivative, to image patients with newly diagnosed lung cancer or indeterminate pulmonary nodules. \[18f\]fluoroglutamine pet may provide additional information that help diagnose lung cancer.


Eligibility criteria:
inclusion criteria: * patients are given the opportunity to participate in the study if 1. age between 18-79; 2. the patient must be able to give informed consent; 3. sexually active subjects agree to use condoms and/or their partners of reproductive potential to use a method of effective birth control during imaging period of 2 weeks; 4. patients can finish pet/ct scan without tranquilizers; 5. patients with a newly diagnosed, untreated primary lung cancer; or patients older than 55, current or former smoking with ≥ 30 pack years, and newly discovered indeterminate pulmonary nodules (7-30 mm diameter) on ct. 6. no chemotherapy, radiotherapy or immune/biologic therapy,or biopsy were allowed between the 18f-fdg and the 4-\[18f\]fluoroglutamine pet/ct. exclusion criteria: * patients with any of the following conditions will be excluded 1. pregnant or lactating patients; 2. patients with active lung infection; 3. inability or refusal to have at least one peripheral intravenous line for intravenous access; 4. from assays obtained \ 1.5\*uln,ast/alt \>2.5 \* uln, albumin\ 2.5 x uln if alp\> 2.5 x uln, creatinine\>1.5\*uln or creatinine clearance \<60ml/min； 5. patients with a history of allergic reaction to this drugs or its analogues； 6. patients with poor compliance; 7. acute major illness
development of personalized health care service in patients with breast cancer

Conditions: Breast Cancer; Lymphedema; Cancer-related Problem/Condition

Summary: in order to develop effective personalized healthcare service program for breast cancer rehabilitation, we designed this study using mobile phone and clinical intervention(feedback coaching).


Eligibility criteria:
inclusion criteria: * breast cancer patient (age over 18), cancer stage under 3, android os smartphone user exclusion criteria: * cancer stage over 4, patients diagnosed with multiple cancer, patient who can not participate rehabilitation exercise program
anxiety and depression levels in cancer patients after self-application of eft (emotional freedom techniques)

Conditions: Depression

Summary: anxiety and depression have been found to be significant co-occurring conditions in cancer patients. this study examines these and other psychological conditions in patients diagnosed with cholangiocarcinoma, a rare cancer of the bile duct, with an average survival time of three to six months post-diagnosis. participants are taught eft in telephone and internet group coaching sessions, and have access to an online support forum. they complete the mini-mental adjustment to cancer scale (mini-mac), eortc quality of life scale, the ptsd checklist, the patient health questionnaire, and a brief health checklist. participants also provide medical records confirming their diagnosis, and markers, both before and after the study. the study is expected to enroll 20-15 cholangiocarcinoma patients, and use a within-subjects, time series, repeated measures design. symptoms are assessed prior to coaching, after four, and again after eight weekly coaching sessions. follow-ups will occur in one month, three months, and one year. it is hypothesized that a drop in the severity of co-occurring psychological symptoms, pain and insomnia may occur after eft coaching.


Eligibility criteria:
inclusion criteria: * diagnosis of cholangiocarcinoma * ability to complete forms and attend phone coaching sessions exclusion criteria: * none

Keywords: depression anxiety pain insomnia cancer cholangiocarcinoma eft (emotional freedom techniques)
effectiveness of inhaled corticosteroids in preschool children with acute dyspnea and wheeze

Conditions: Wheezing; Dyspnea

Summary: the aim of the study is to investigate whether inhaled corticosteroids after a first hospital admission for acute dyspnea and wheeze is effective in reducing subsequent episodes of these complaints in children aged 1 to 4 years.

symptoms of dyspnea and wheeze occur frequently in young children with a cumulative incidence of 33% before the age of 3 and up to 50% by the age of 6 years. most wheezing episodes in preschool children are associated with viral upper respiratory tract infections (episodic viral wheeze). the majority of children with episodic viral wheeze have become asymptomatic by the age of 6 years. about one in three preschool children with recurrent wheeze continue to wheeze after the age of six years, and these children are usually diagnosed with asthma. two clinical phenotypes of recurrent wheezing in preschool children can be distinguished. children with episodic viral wheeze only wheeze with viral upper respiratory tract infections and are symptom free in between episodes. a minority of children wheeze during upper respiratory tract infection and with other trigger factors (such as smoke, fog, exercise) and this is defined as multiple trigger wheeze. inhaled corticosteroids (ics) have been shown to be effective in preschool children with multiple trigger wheeze, but the effect is smaller than that in older children. this justifies a more critical approach towards such therapy, for example by prescribing a trial of ics for a period of 3 months and evaluating the effect afterwards. little research has been performed on the effect of ics in preschool children with episodic viral wheeze. a high dose of ics (\>1600 ug/d) during an acute episode of dyspnea and wheezing has been shown to be effective, but in a number of small clinical trials maintenance treatment with ics did not have an effect on the number and severity of episodes of viral wheezing. contradictory results have been published about the effect of ics in infants and preschool children with respiratory syncytial virus bronchiolitis. some studies showed a reduction of wheezing episodes after rsv bronchiolitis in children treated with ics, two other studies did not show any positive effect. prescribing ics in preschool children can result in adverse effects such as a reduced height growth. because of the lack of evidence of effect of ics in episodic viral wheeze, guidelines advise a critical approach towards prescribing ics in episodic viral wheeze.

Eligibility criteria:
inclusion criteria: * children that are admitted to the paediatric ward of the isala klinieken in zwolle for the first time with acute dyspnea and wheezing * age 1 - 4 years * child and parents must understand the dutch language well * informed consent exclusion criteria: * previous use of medication different than short-acting β2-agonists before hospital admission * proven rsv bronchiolitis * crackles during auscultation of the lungs (suggestive for rsv bronchiolitis)

Keywords: child wheezing dyspnea inhaled corticosteroids
laterally rotated flap for soft tissue augmentation around maxillary loaded osseointegrated dental implant

Conditions: Implant Tissue Failure; Dental Implant Failed; Peri-Implantitis

Summary: peri-implant mucositis is one of the most common peri-implant diseases. it was reported in more than 20% of the subjects rehabilitated with dental implants (lee et al. 2017; rodrigo et al. 2018; wada et al. 2019). furthermore, a significant association was found between peri-implant mucositis, and smoking, implant maintenance and peri-implant soft tissue characteristics (wada et al. 2019). soft tissue quality and volume of the peri-implant mucosa are considered important factors in the prognosis of osseointegrated implants. linkevicius et al. showed that if its soft tissue thickness was less than 2 mm, crestal bone loss might occur (linkevicius et al. 2009). in addition, when soft tissue width was evaluated, a wider soft tissue band was related to minimal bone remodeling (linkevicius et al. 2015). lin et al. reported in a systematic review and meta-analysis that a lack of keratinized tissue (kt) around osseintegrated implants was associated with plaque accumulation, peri-implant tissue inflammation, soft tissue recession and attachment loss (lin et al. 2013). moreover, recent studies established the need of a minimal band of 2 mm of kt around osseointegrated implants, and showed that a band less than 2 mm was associated with more brushing discomfort, plaque accumulation, tissue inflammation and marginal bone apical displacement, concluding that a kt\>2 mm had a protective effect on peri-implant tissues (souza et al. 2015, perussolo et al. 2018, monje et al. 2019). furthermore, peri-implant tissue diseases have also been related to an irregular compliance in situations of lack of kt (monje et al. 2019). in the presence of peri-implant horizontal and/or vertical soft tissue deficiencias, soft tissue augmentation has been considered a priority, even prior or instead of bone augmentation (burkhardt et al. 2008, zucchelli et al. 2013).


Eligibility criteria:
inclusion criteria: implant with soft tissue recession plaque index score less than 30% no relevant systemic disease smokers (less than 20 cigars/day) exclusion criteria: pregnancy-lactation relevant systemic disease
a study of 6-month duration to evaluate the weight loss effect of various doses of cp-945,598 in obese subjects

Conditions: Obesity

Summary: to evaluate the effect of 6-month administration of cp-945,598 on: * weight loss and waist circumference, * blood pressure, cholesterol, glucose * other biochemical variables like insulin, leptin, ghrelin, adiponectin, pai 1, tnf-î± and hscrp * the relationship between the concentration of the drug on the blood and the above parameters * physical and psychosocial functioning, weight related symptoms, treatment satisfaction, appetite/hunger/satiety/craving and mood, anxiety, anhedonia and depression


Eligibility criteria:
inclusion criteria: * male and/or female subjects without clinically relevant abnormalities identified by a detailed medical history, full physical examination, including blood pressure and pulse rate measurements, 12 lead ecg and clinical laboratory tests * body mass index (bmi) â³30 and \<40 kg/m2, for subjects with no additional * co morbidities; bmi â³27 kg/m2 and \<40 kg/m2, for subjects with co morbidities \[history of essential hypertension and/or dyslipidemia defined as high ldl (â³160 mg/dl) or high total cholesterol (â³240 mg/dl)\]; exclusion criteria: * subjects with resting sitting systolic blood pressure of 140 mmhg or greater or diastolic blood pressure of 90 mmhg or greater. * subjects with type 2 diabetes or fasting blood glucose concentration â³126 mg/dl; * subjects with a history of eating disorders like anorexia nervosa or bulimia nervosa * subjects on prescription and non-prescription appetite or weight modifying drugs
predictive factors associated to bile cultures and antibiogram resistance in patients with laparoscopic cholecystectomy

Conditions: Biliary Infection; Antibiotic Resistant Strain

Summary: the bacilo study was designed with the objective of having robust data on local epidemiological bacterial colonisation information on bile cultures with patients taken to laparoscopic cholecystectomy in our institution to find which predictive factors are associated with culture positivity and antibiotic resistance patterns. secondary endpoints include evaluating demographical, clinical and surgical variables and establishing comparison between both positive and negative bile cultures and between antibiotic sensitive and resistant microorganism strain isolations.

bacilo is single-centre, observational, analytical, prospective study with a prognostic prediction model with the objective of identifying predictive factors associated with microbial and antibiotic resistance patterns in bile cultures of patients taken to laparoscopic cholecystectomy in our institution. primary outcomes are bile culture positivity and phenotypical resistance antibiogram patterns while secondary outcomes include demographic, clinical and surgical characteristics and surgical outcomes. the main objective is to determine predictive factors using a prediction model, variables included are: age, diabetes mellitus, c-reactive protein test, choledocholithiasis/ercp, cholecystitis and severity of cholecystitis according to the 2018 tokyo guidelines.this in the nature of describing the relationship between bile culture positivity and phenotypical antibiogram resistance patterns in our institution, and establish thus better treatment strategies based on higher quality local evidence.

Eligibility criteria:
inclusion criteria: * patients included must be over 18 years of age and be taken to laparoscopic cholecystectomy between march 2024 and february 2026 in any institution of the méderi hospital network (hospital universitario mayor and hospital universitario barrios unidos), have signed the written informed consent to be included in the study and have both bile culture and antibiogram. exclusion criteria: * - patients that will be taken to laparoscopic cholecystectomy with another concomitant surgical procedure (including but not exclusive to gastrectomy, pancreatoduodenectomy, oesophagectomy, splenectomy, abdominal wall reconstruction, colectomy, amongst others) with the exception of umbilical herniorrhaphy. * patients without a postoperative control appointment. * patients with an untreated hiv diagnosis. * patients with diagnosis of a malignant gallbladder or biliary tract disease documented preoperatively.

Keywords: biliary infection bactibilia antibiotic resistance laparoscopic cholecystectomy